drugset / Trial / NCT07255209

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

NCT07255209

Phase 3 Recruiting 180 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.

Timeline

Start
2025-12-29
Primary completion
2027-10-31
Completion
2028-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mazdutide Protein / enzyme biologic

Indications

No indication recorded.